BSC approach at each strength? [Dissolution / BCS / IVIVC]

posted by Mauricio Sampaio  – Brazil, 2019-07-19 22:29 (639 d 02:45 ago) – Posting: # 20407
Views: 2,705

Dear all, happy to write here again!

According ICH guideline M9 on biopharmaceutics classification system based biowaivers, is said: "For products with more than one strength the BCS approach should be applied for each strength, i.e., it is expected that test and reference product dissolution profiles are compared at each strength."

My question is: If a biowaiver test (vitro) according BCS replaces a bioequivalence test (in vivo), why not performing just one BCS approach for high strengh (test and reference) and after to do a compare by dissolution test of Tested product (high strengh) versus Test product (low strengh) in an only dissolution medium?

What is the technical reason to performing the BSC approach at each strength?

I really appreciate your opinion!

Best regards

Complete thread:

Activity
 Admin contact
21,419 posts in 4,475 threads, 1,509 registered users;
online 11 (0 registered, 11 guests [including 2 identified bots]).
Forum time: Monday 01:14 CEST (Europe/Vienna)

There is one certainty in drug development
and statistics that one can depend on:
the data are always late.    Scott Patterson and Byron Jones

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5